Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares closed at $25.01 on July 31, 2026, up approximately 2.8% over the trailing 30 days, yet the stock remains below both its 50-day and 200-day moving averages.
• The company offers one of the highest dividend yields in the S&P 500 at roughly 7%, supported by a $0.43 quarterly payout, but a payout ratio above 130% raises sustainability questions.
• First-quarter 2026 results beat expectations with EPS of $0.75 and revenue of $14.45 billion, though full-year guidance of $2.80–$3.00 per share represents a decline from 2025's $3.22.
• Patent expirations on blockbuster drugs including Eliquis (2028), Ibrance (2027), and Vyndaqel (2028) create a multi-year revenue headwind that the market continues to price in.
• Pfizer is betting on its obesity candidate berobenatide (MET-097i) and a growing oncology portfolio to reignite long-term growth, with over 20 obesity studies planned in 2026 alone.

Current Market Snapshot

Pfizer Inc. (PFE) has traded in a relatively narrow band in recent weeks, hovering near the $25 level after rebounding from a late-June trough near $23.67. The stock's forward price-to-earnings multiple has compressed to roughly 8.5x, a deep discount to the large-cap pharmaceutical peer group and to Pfizer's own five-year average. With a 52-week range of $23.11 to $28.75 and a beta of just 0.35, the stock exhibits low volatility relative to the broader market. However, technical signals remain cautious: PFE has traded below its 50-day SMA (~$25.22) and 200-day SMA (~$26.18) since mid-June. Institutional ownership stands at approximately 68%, though several large funds trimmed positions during the first quarter, reflecting a broader wait-and-see posture among professional investors.

Pfizer (PFE) Business Overview and Competitive Position

Pfizer is a multinational biopharmaceutical company headquartered in New York City, with operations spanning discovery research, clinical development, regulatory affairs, manufacturing, and global commercial distribution. Its therapeutic reach covers oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care, anti-infectives, and vaccines. Oncology now represents roughly 27% of total revenue, bolstered by the 2023 acquisition of Seagen. Key in-line products include the anticoagulant Eliquis, the breast cancer drug Ibrance, the transthyretin amyloidosis treatment Vyndaqel, and the COVID-19 vaccine Comirnaty. Pfizer's competitive moat rests on its massive global commercial infrastructure, deep R&D capabilities, and a portfolio that generated $62.6 billion in 2025 revenue. That said, the company's post-pandemic transition has been challenging, and it now trails rivals like Eli Lilly (LLY) and Novo Nordisk (NVO) in market valuation and growth momentum.

Recent Developments Driving PFE

Pfizer and BioNTech (BNTX) secured European Commission authorization in late July for their updated COVID-19 vaccine targeting the XFG variant, covering all EU member states for individuals six months and older. On the oncology front, Pfizer won FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, marking the first platinum-free option in this setting and reinforcing the company's ambition to build eight or more blockbuster oncology drugs by 2030.

On the analyst front, sentiment remains muted. Royal Bank of Canada upgraded PFE from Underperform to Sector Perform with a $25 target in June, while JPMorgan trimmed its target to $28 and Bank of America lowered its target to $26 in July. Guggenheim remains one of the few bullish voices with a $35 target and a Buy rating. The consensus rating sits at Hold with an average target of $28.50, implying roughly 14% upside from current levels.

Meanwhile, the dividend narrative continues to divide opinion. Pfizer paid approximately $9.8 billion in dividends in 2025 and roughly $4.8 billion through the first half of 2026. Management has stated publicly that maintaining the dividend is a priority, but the trailing payout ratio exceeding 130% leaves little room for error. The company also faces expanded international patent lawsuits from Arbutus Biopharma and Genevant Sciences related to lipid nanoparticle technology used in mRNA COVID-19 vaccines, adding a layer of legal uncertainty.

Trending AI Robots

For investors seeking data-driven strategies in a complex pharmaceutical landscape, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered bots that trade thousands of tickers across multiple strategies, timeframes, and risk profiles, but only the most relevant and consistently high-performing bots are featured in this section. These bots employ technical analysis, pattern recognition, and proprietary algorithms to identify trading opportunities without emotional bias. Bots vary by holding period — from intraday to swing trading to longer-term positions — and by underlying strategy, allowing users to align selections with their individual investment approach. Exploring the Trending AI Robots page can help traders discover automated tools designed to navigate markets with discipline and precision.

2026 Outlook and What Investors Should Watch

Pfizer's 2026 outlook centers on execution across three critical fronts. First, the company guided for full-year revenue between $59.5 billion and $62.5 billion and adjusted EPS of $2.80 to $3.00 — ranges that imply flat to slightly negative growth year-over-year, weighed down by fading COVID product sales and an estimated $1.5 billion revenue headwind from loss-of-exclusivity events. Second, the obesity pipeline is entering a pivotal phase: Pfizer plans to initiate more than 20 obesity studies in 2026, including 10 Phase III trials for berobenatide (MET-097i), a monthly GLP-1 receptor agonist acquired through the Metsera deal. Phase II data showed encouraging efficacy and tolerability, but the drug remains years behind entrenched competitors.

Third, the oncology division must continue delivering. Padcev, Lorbrena, and the Braftovi-Mektovi combination all posted operational growth in Q1, and the PF-08634404 bispecific antibody (PD-1/VEGF) in-licensed from 3SBio enters pivotal studies this year. Investors should monitor upcoming data readouts, regulatory decisions, and any updates to the dividend policy. Macroeconomic factors — including Medicare Part D redesign under the Inflation Reduction Act and international drug pricing pressures — also warrant close attention as policy developments could reshape revenue trajectories across Pfizer's portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations